Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)

6 Months Ended

Jun. 30, 2025

Cash, Cash Equivalents, and Short-Term Investments [Abstract]

Schedule of Cash, Cash Equivalents and Marketable Securities

Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:


	As of June 30, 2025
(in thousands)	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
Cash and cash equivalents	$	158,702	$	—	$	—	$	158,702
Commercial paper	32,124		—		(8)		32,116
U.S. government agency bonds	27,580		62		(3)		27,639
Corporate debt securities	12,370		19		(1)		12,388
Money market	100		—		—		100
Certificates of deposit	53		—		—		53
	$	230,929	$	81	$	(12)	$	230,998
Included in cash and cash equivalents	$	158,702	$	—	$	—	$	158,702
Included in marketable securities	72,227		81		(12)		72,296
Total cash, cash equivalents, and marketable securities	$	230,929	$	81	$	(12)	$	230,998


	As of December 31, 2024
(in thousands)	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
Cash and cash equivalents	$	213,752	$	—	$	—	$	213,752
Commercial paper	18,082		3		(4)		18,081
U.S. government agency bonds	16,524		1		(7)		16,518
Corporate debt securities	1,446		—		(2)		1,444
Money market	100		—		—		100
Certificate of deposit	51		—		—		51
	$	249,955	$	4	$	(13)	$	249,946
Included in cash and cash equivalents	$	213,752	$	—	$	—	$	213,752
Included in marketable securities	36,203		4		(13)		36,194
Total cash, cash equivalents, and marketable securities	$	249,955	$	4	$	(13)	$	249,946

Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total shown in the Consolidated Statements of Cash Flows.


	As of June 30,
(in thousands)	2025		2024
Cash and cash equivalents	$	158,702	$	209,335
Restricted cash	3,313		3,022
Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows	$	162,015	$	212,357

AMICUS THERAPEUTICS, INC. 10-Q